AbbVie JP Morgan 2022_Final.pdf

1、J.P.Morgan Healthcare Conference|January 11,20221J.P.Morgan Healthcare Conference Rob MichaelVice Chairman,Finance and Commercial OperationsChief Financial OfficerJanuary 11,2022J.P.Morgan Healthcare Conference|January 11,20222Forward-Looking Statements and Non-GAAP Financial informationSome stateme

2、nts in this presentation are,or may be considered,forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.The words“believe,”“expect,”“anticipate,”“project”and similar expressions,among others,generally identify forward-looking statements.AbbVie cautions that

3、these forward-looking statements are subject to risks and uncertainties,including the impact of the COVID-19 pandemic on AbbVies operations,results and financial results,that may cause actual results to differ materially from those indicated in the forward-looking statements.Such risks and uncertain

4、ties include,but are not limited to,failure to realize the expected benefits of the Allergan acquisition,failure to effectively integrate Allergans businesses,challenges to intellectual property,competition from other products,difficulties inherent in the research and development process,adverse lit

5、igation or government action,and changes to laws and regulations applicable to our industry.Additional information about the economic,competitive,governmental,technological and other factors that may affect AbbVies operations is set forth in Item 1A,“Risk Factors,”of AbbVies 2020 Annual Report on Fo

6、rm 10-K,which has been filed with the Securities and Exchange Commission,as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update,supplement or supersede such information.AbbVie undertakes no obliga